Clinical value of gene detection in metastatic prostate cancer / 中华泌尿外科杂志

ABSTRACT

The incidence of prostate cancer has increased over the past several years and it has become a major disease that seriously harms male health. Advanced prostate cancer is a heterogeneous disease with poor outcomes, the median overall survival of advanced prostate cancer usually less than two years. Clinical challenges include determining the optimal sequencing of systemic therapies and implementing biomarker-driven treatment approaches. The emergence of precision treatment has brought about a diagnosis and treatment strategy based on molecular testing, which provides the possibility for the formulation of individualized treatment plans.